<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924989</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-906-301</org_study_id>
    <secondary_id>2009-012820-97</secondary_id>
    <nct_id>NCT00924989</nct_id>
  </id_info>
  <brief_title>A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma</brief_title>
  <acronym>GALACCTIC</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent
      OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who
      received at least 1 but no more than 2 prior drug regimens
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo
      (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC,
      and Eastern Cooperative Oncology Group (ECOG) performance status, and use of &gt;= 1 oral
      antihyperglycemic therapy at randomization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2009</start_date>
  <completion_date type="Actual">October 8, 2012</completion_date>
  <primary_completion_date type="Actual">July 11, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival of single agent OSI-906 versus placebo</measure>
    <time_frame>33 months</time_frame>
    <description>Time from date of randomization until time of documented death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomization to disease progression based on RECIST version 1.1 or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD), based on RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients with a best overall response of CR or PR based on RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
    <description>Time from date of the first documented response (CP/PR) to documented progression or death due to underlying cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed via physical exams, vital signs, laboratory assessments, electrocardiograms, and adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-906</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
    <other_name>linsitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered orally</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adrenocortical carcinoma that is locally advanced or
             metastatic and not amenable to surgical resection.

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             (version 1.1).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &lt;= 2

          -  Predicted life expectancy &gt;= 12 weeks.

          -  At least 1 but no more than 2 prior drug regimens (including molecular targeted
             therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally
             advanced/metastatic ACC.

          -  A minimum of 3 weeks must have elapsed between the end of prior treatment and
             randomization.

          -  All patients must have received prior mitotane, either as neoadjuvant, adjuvant, or
             locally advanced/metastatic therapy.

          -  Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens
             or as systemic cytotoxic chemotherapy.

          -  Prior radiation therapy is permitted provided patients have recovered from the acute,
             toxic effects of radiotherapy prior to randomization.

          -  A minimum of 21 days must have elapsed between the end of radiotherapy and
             randomization.

          -  Prior surgery is permitted provided that adequate wound healing has occurred prior to
             randomization.

          -  Fasting glucose &lt; = 150 mg/dL (8.3 mmol/L).

          -  Adequate hematopoietic, hepatic, and renal function defined as follows: Neutrophil
             count &gt;= 1.5 x 10^9 /L;

          -  Platelet count &gt;= 100 x 10^9 /L;

          -  Bilirubin &lt;= 1.5 x Upper Limit of Normal (ULN);

          -  AST and ALT &lt;= 2.5 x ULN, or &lt;= 5 x ULN if patient has documented liver metastases or
             received prior mitotane therapy; and

          -  Serum creatinine &lt;= 1.5 x ULN or &lt;= 2.0 x ULN if the patient has received prior
             cisplatin.

          -  Patients, both males and females, with reproductive potential (ie, menopausal for less
             than 1 year and not surgically sterilized) must agree to practice effective
             contraceptive measures throughout the study.

          -  Women of childbearing potential must provide a negative pregnancy test (serum or
             urine) within 14 days prior to randomization.

          -  Patients must provide verbal and written informed consent to participate in the study.

          -  Radiologically-confirmed progressive disease within 6 months prior to randomization.

          -  Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if
             the dose has been stable for &gt;= 4 weeks at the time of randomization.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring
             insulinotropic or insulin therapy.

          -  Prior IGF-1R inhibitor therapy.

          -  Malignancy other than ACC within the past 3 years. Exceptions: resected basal cell or
             squamous cell carcinoma of the skin; cured in situ cervical carcinoma; cured ductal
             carcinoma in situ of the breast; and/or cured superficial bladder cancer.

          -  History of significant cardiovascular disease unless the disease is well-controlled.

          -  Significant cardiac diseases includes second/third degree heart block; clinically
             significant ischemic heart disease; mean QTcF interval &gt; 450 msec at screening;

          -  poorly controlled hypertension; congestive heart failure of New York Heart Association
             (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest,
             but ordinary physical activity results in fatigue, palpitation, or dyspnea).

          -  History of cerebrovascular accident (CVA) within 6 months prior to randomization or
             that resulted in ongoing neurologic instability.

          -  Use of drugs that have a risk of causing QT interval prolongation within 14 days prior
             to Day 1 dosing.

          -  Active infection or serious underlying medical condition (including any type of active
             seizure disorder within 12 months prior to randomization) that would impair the
             ability of the patient to receive study drug.

          -  History of any psychiatric condition that might impair the patient's ability to
             understand or to comply with the requirements of the study or to provide informed
             consent.

          -  Pregnant or breast-feeding females.

          -  Symptomatic brain metastases that are not stable, require steroids, are potentially
             life threatening, or that have required radiation within 28 days prior to
             randomization.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TGen Clinical Research Service at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Medical School</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Cancer Trials Services</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital Department of Endocrinology</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMH - Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille, Clinique Endocrinologique Marc Linquette</name>
      <address>
        <city>Lille</city>
        <zip>59037 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273 cedex 09</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin-Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75679 Cedex 14</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets Klinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum (MMC)</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James' University hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=230</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <disposition_first_submitted>July 10, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 10, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 12, 2013</disposition_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenocortical carcinoma</keyword>
  <keyword>OSI-906</keyword>
  <keyword>ACC</keyword>
  <keyword>GALACCTIC</keyword>
  <keyword>Insulin-like growth factor-1 receptor (IGF-1R)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

